Traders sold shares of Zoetis Inc (NYSE:ZTS) on strength during trading hours on Friday. $12.64 million flowed into the stock on the tick-up and $30.22 million flowed out of the stock on the tick-down, for a money net flow of $17.58 million out of the stock. Of all stocks tracked, Zoetis had the 0th highest net out-flow for the day. Zoetis traded up $0.56 for the day and closed at $89.24
A number of research analysts have commented on the company. Zacks Investment Research upgraded Zoetis from a “hold” rating to a “buy” rating and set a $100.00 price objective on the stock in a research report on Wednesday, October 17th. BMO Capital Markets reiterated a “hold” rating and issued a $82.00 price objective on shares of Zoetis in a research report on Thursday, August 2nd. Cantor Fitzgerald set a $98.00 price objective on Zoetis and gave the company a “buy” rating in a research report on Thursday, August 2nd. Stifel Nicolaus lowered Zoetis from a “buy” rating to a “hold” rating and set a $95.00 price objective on the stock. in a research report on Tuesday, August 21st. They noted that the move was a valuation call. Finally, Argus increased their price objective on Zoetis from $90.00 to $103.00 and gave the company a “buy” rating in a research report on Tuesday, August 14th. Six analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $94.00.
The company has a quick ratio of 2.63, a current ratio of 4.06 and a debt-to-equity ratio of 3.04. The stock has a market capitalization of $42.88 billion, a PE ratio of 29.36, a price-to-earnings-growth ratio of 1.76 and a beta of 0.97.
The business also recently declared a quarterly dividend, which will be paid on Monday, December 3rd. Stockholders of record on Tuesday, November 20th will be given a $0.126 dividend. The ex-dividend date is Monday, November 19th. This represents a $0.50 annualized dividend and a dividend yield of 0.56%. Zoetis’s dividend payout ratio is currently 20.83%.
In other news, insider Kristin C. Peck sold 11,500 shares of the firm’s stock in a transaction on Monday, November 12th. The stock was sold at an average price of $94.78, for a total value of $1,089,970.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Juan Ramon Alaix sold 150,306 shares of the firm’s stock in a transaction on Thursday, November 8th. The stock was sold at an average price of $94.96, for a total value of $14,273,057.76. Following the completion of the transaction, the chief executive officer now owns 246,319 shares in the company, valued at $23,390,452.24. The disclosure for this sale can be found here. Insiders sold a total of 163,806 shares of company stock worth $15,547,088 over the last 90 days. 0.35% of the stock is owned by corporate insiders.
Several large investors have recently bought and sold shares of the company. Valeo Financial Advisors LLC boosted its position in shares of Zoetis by 34.4% in the 2nd quarter. Valeo Financial Advisors LLC now owns 2,210 shares of the company’s stock worth $202,000 after purchasing an additional 566 shares during the last quarter. Sunbelt Securities Inc. raised its stake in Zoetis by 16.2% during the 3rd quarter. Sunbelt Securities Inc. now owns 4,250 shares of the company’s stock worth $389,000 after buying an additional 594 shares during the period. Dupont Capital Management Corp raised its stake in Zoetis by 2.5% during the 2nd quarter. Dupont Capital Management Corp now owns 24,508 shares of the company’s stock worth $2,088,000 after buying an additional 601 shares during the period. WealthPLAN Partners LLC raised its stake in Zoetis by 20.0% during the 3rd quarter. WealthPLAN Partners LLC now owns 3,661 shares of the company’s stock worth $324,000 after buying an additional 611 shares during the period. Finally, Rehmann Capital Advisory Group raised its stake in Zoetis by 40.5% during the 2nd quarter. Rehmann Capital Advisory Group now owns 2,190 shares of the company’s stock worth $187,000 after buying an additional 631 shares during the period. Institutional investors and hedge funds own 89.14% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Traders Sell Shares of Zoetis (ZTS) on Strength (ZTS)” was first reported by WKRB News and is owned by of WKRB News. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at https://www.wkrb13.com/2018/11/25/traders-sell-shares-of-zoetis-zts-on-strength-zts.html.
About Zoetis (NYSE:ZTS)
Zoetis, Inc discovers, develops and manufactures a portfolio of animal health medicines and vaccines. Its products are complemented by diagnostic products, genetic tests, bio devices and services. These are designed to meet the needs of veterinarians and the livestock farmers and companion animal. The firm provides its services though five categories namely, anti-invectives, vaccines, parasitic ides, medicated feed additives, and other pharmaceuticals.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.